Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 10.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 179,318 shares of the biotechnology company's stock after selling 20,083 shares during the period. New York State Common Retirement Fund owned 0.31% of Ascendis Pharma A/S worth $26,774,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ASND. Avoro Capital Advisors LLC raised its stake in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after buying an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP raised its position in shares of Ascendis Pharma A/S by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company's stock valued at $616,050,000 after purchasing an additional 44,580 shares during the last quarter. Capital International Investors boosted its stake in Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company's stock worth $331,261,000 after purchasing an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company's stock valued at $233,348,000 after purchasing an additional 93,185 shares in the last quarter.

Ascendis Pharma A/S Price Performance

ASND stock traded up $0.49 during midday trading on Monday, hitting $125.77. 486,062 shares of the stock traded hands, compared to its average volume of 444,783. Ascendis Pharma A/S has a 1-year low of $86.54 and a 1-year high of $161.00. The stock's fifty day simple moving average is $133.42 and its 200-day simple moving average is $133.56. The firm has a market cap of $7.63 billion, a P/E ratio of -13.62 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, research analysts predict that Ascendis Pharma A/S will post -7.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ASND has been the subject of several research reports. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 17th. Wells Fargo & Company boosted their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Oppenheimer reissued an "outperform" rating and issued a $190.00 price objective (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Monday. Finally, TD Cowen increased their price target on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $195.92.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.